Outcomes Reporting
Patients face an increasingly complex decision when deciding where to go for their cancer treatment. There are several factors that can aid in that decision-making process including location, center designation, physician experience, physician referral, health plan coverage, and options for treatment. In addition to these factors, nationally accepted quality measures, outcome data, and patient satisfaction information can also be helpful tools in comparisons between cancer treatment centers or hospitals.
ACSO/NCCN Quality Measures
Smilow Cancer Hospital at Yale-New Haven and Yale Cancer Center acknowledge the seven American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) evidence-based quality guidelines for breast and colorectal cancers. The latest performance data for the Breast Cancer Program and Gastrointestinal Cancers Program in the treatment of these diseases is listed below.
Colorectal Cancer Performance Rates
| Performance Measure |
4 |
5 |
6 |
7 |
8 |
| Adjuvant Chemotherapy (C/CT)1 |
80% |
88% |
73% |
88% |
% |
12 Regional Lymph Nodes
(C/12RLN)2 |
89% |
88% |
90% |
91% |
95% |
| Adjuvant Radiation Therapy (R/RT)3 |
% |
80% |
83% |
% |
% |
| Postoperative Adjuvant Chemotherapy Therapy (R/CT)4 |
- |
- |
50% |
89% |
88% |
- Adjuvant chemotherapy is considered or administered within 4 months of diagnosis for patients under the age of 80 with stage III (lymph node positive) colon cancer.
- At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.
- Radiation therapy is considered or administered within 6 months of diagnosis for patients under the age of 80 with clinical or pathologic T4N1M0 or stage III colorectal cancer after receiving surgical resection for rectal cancer.
- Postoperative adjuvant chemotherapy is administered within 9 months (270 days) of diagnosis to patients under the age of 80 with clinical or pathologic AJCC Stage II or Stage III receiving surgical resection for rectal cancer.
NMDP Allogeneic Bone Marrow Transplant Center Data
The National Marrow Donor Program tracks data on patients who have received a transplant at accredited United States Transplant Centers. Yale Cancer Center's actual results are above the predicted survival range. The following chart shows how Yale Cancer Center compares to Transplant Centers in the United States reporting more than 50 allogeneic transplants during the most recent reporting period (2004 - 2008):
Transplant Centers Comparison Chart
| Institution |
# of Patients |
One-Year Survival |
Predicted Survival |
| Yale University/Yale-New Haven Hospital |
107 |
73% |
63% |
| B |
115 |
74% |
58% |
| C |
530 |
68% |
58% |
| D |
149 |
68% |
59% |
| E |
455 |
66% |
58% |
| F |
334 |
66% |
65% |
| G |
118 |
66% |
55% |
| H |
283 |
65% |
63% |
| I |
218 |
64% |
62% |
| J |
228 |
64% |
53% |
| K |
83 |
64% |
58% |
| L |
198 |
63% |
58% |
| M |
154 |
62% |
61% |
| N |
115 |
62% |
60% |
| O |
94 |
62% |
66% |
| P |
102 |
61% |
62% |
| Q |
674 |
60% |
59% |
| R |
351 |
60% |
57% |
| S |
160 |
60% |
58% |
| T |
724 |
59% |
54% |
| U |
125 |
59% |
62% |
| V |
72 |
59% |
58% |
| W |
263 |
58% |
59% |
| X |
210 |
58% |
58% |
| Y |
224 |
57% |
59% |
| Z |
162 |
56% |
53% |
| AA |
149 |
56% |
57% |
| BB |
81 |
56% |
54% |
| CC |
269 |
55% |
54% |
| DD |
146 |
55% |
60% |
| EE |
148 |
54% |
56% |
| FF |
93 |
54% |
56% |
| GG |
332 |
53% |
50% |
| HH |
184 |
53% |
57% |
| II |
75 |
53% |
58% |
| JJ |
65 |
52% |
48% |
| KK |
294 |
51% |
54% |
| LL |
147 |
51% |
54% |
| MM |
|
51% |
55% |
| NN |
70 |
51% |
59% |
| OO |
139 |
50% |
58% |
| PP |
118 |
50% |
55% |
| QQ |
81 |
49% |
61% |
| RR |
126 |
48% |
47% |
| SS |
72 |
48% |
58% |
| TT |
103 |
47% |
57% |
| UU |
96 |
46% |
51% |
| VV |
84 |
43% |
52% |
| WW |
142 |
42% |
53% |
| XX |
132 |
42% |
53% |
| YY |
90 |
36% |
42% |
*based on overall disease condition of treated patients, measured on a scale from 1 (low risk) to 5 (high risk).